Sangamo Therapeutics Inc (NAS:SGMO)
$ 2.3 0.16 (7.48%) Market Cap: 479.89 Mil Enterprise Value: 468.41 Mil PE Ratio: 0 PB Ratio: 12.23 GF Score: 47/100

Sangamo Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 12:00AM GMT
Release Date Price: $10.27 (+3.01%)
Unidentified Analyst

Thank you so much for joining us today at the Bank of America Merrill Lynch health care conference here. Today it's my pleasure to have Sandy Macrae, the CEO from Sangamo, a leader in gene therapy and gene editing. And we're all looking forward to the discussion.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Absolutely, nice to be here.

Questions & Answers

Unidentified Analyst;Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President &

Yes. So obviously, Sangamo has been in the gene editing field for quite a while. And can you broadly talk through the evolution of your technology for the past few years and given that there is interest arising over the gene therapy and gene editing field overall? And can you also speak to the editing efficiency as well as a safety comparing to your other emerging technology as well such as CRISPR and maybe RCUS, and maybe some more recently talking about non-nucleus edited probe technologies?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot